Home

calendar Concealment march puma biotechnology Specimen Subordinate Economy

Puma Biotechnology
Puma Biotechnology

Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology, Inc. | LinkedIn

Puma Biotechnology
Puma Biotechnology

Puma Biotechnology
Puma Biotechnology

Why Puma Biotechnology Is Soaring Today | Nasdaq
Why Puma Biotechnology Is Soaring Today | Nasdaq

Puma Biotechnology
Puma Biotechnology

Puma Biotechnology
Puma Biotechnology

Puma Biotechnology
Puma Biotechnology

Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology, Inc. | LinkedIn

Puma Biotechnology
Puma Biotechnology

Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) |  Seeking Alpha
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha

Puma Biotechnology, Inc. 2022 Q1 - Results - Earnings Call Presentation  (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology, Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha

Puma Biotechnology Inc. | BioWorld
Puma Biotechnology Inc. | BioWorld

Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Puma Biotechnology Announces $10 Million Private Placement | Business Wire

Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual  Conference (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha

Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology - Crunchbase Company Profile & Funding

Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of  the Phase 2 SUMMIT 'Basket' Trial of Neratinib at the ASCO 2022 Annual  Meeting
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT 'Basket' Trial of Neratinib at the ASCO 2022 Annual Meeting

Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial  for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019

Puma Biotechnology, Inc. 2020 Current Report 8-K
Puma Biotechnology, Inc. 2020 Current Report 8-K

PumaBiotech (@pumabiotech) / Twitter
PumaBiotech (@pumabiotech) / Twitter

Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer  Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting

Puma Biotechnology (PBYI) Stock Climbs On Orphan Drug Designation | Alpha  Stock News
Puma Biotechnology (PBYI) Stock Climbs On Orphan Drug Designation | Alpha Stock News

Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet

Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Puma Biotechnology Announces $10 Million Private Placement | Business Wire

Puma Biotechnology Announces New Updates And Changes In Breast Cancer  Treatment
Puma Biotechnology Announces New Updates And Changes In Breast Cancer Treatment